Viewing Study NCT02310451



Ignite Creation Date: 2024-05-06 @ 3:32 AM
Last Modification Date: 2024-10-26 @ 11:35 AM
Study NCT ID: NCT02310451
Status: COMPLETED
Last Update Posted: 2023-09-08
First Post: 2014-11-13

Brief Title: Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma Role of Exosomes
Sponsor: Centre Hospitalier Universitaire de Nice
Organization: Centre Hospitalier Universitaire de Nice

Study Overview

Official Title: Pilot Study of Exosomes Before and After BRAF Inhibitor Therapy in Patients With Advanced Unresectable or Metastatic BRAF Mutation-positive Melanoma
Status: COMPLETED
Status Verified Date: 2023-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: EXOSOMES
Brief Summary: Recent progresses have been made in the treatment of metastatic melanoma nevertheless improved patient survival is still limited because of primary resistance and relapses It is therefore important to continue to understand the molecular mechanisms involved in melanoma development and progression to improve the management of patients

Drugs such as the alkylating agents temozolomide and fotemustine or vemurafenib trigger senescence-like phenotypes in melanoma cells It is now known that senescent cells secrete some factors that exert a pro-tumoral role but the potential existence and the role of insoluble factors remain undetermined

Preliminary results from the investigators laboratory indicate the presence in the senescent secretome of exosomes microvesicles involved in intercellular communication immunomodulatory functions and tumorigenesis Several studies showed that these vesicles shape the tumor microenvironment and contribute to the migration of cancer cells

Their interest in oncology as a prognostic factor and marker of therapeutic response is increasing

Thus our project aims to study the effect of exosomes produced by senescent melanoma cells in the development and progression of melanoma in vitro and in vivo using cell cultures and animal models

In addition the investigator propose a pilot study whose objective is to determine the effect of vemurafenib on nanovesicles produced by patients with advanced unresectable or metastatic melanoma

The investigator hope to show that exosomes participate in the process of drug resistance and relapse with the goal of developing with the exosomes study theranostic tools for personalized care in patients
Detailed Description: Metastatic melanoma is an aggressive tumor with a 5-year survival rate of about 6 months Although recent progresses have been made in the treatment of metastatic melanoma improved patient survival is still limited because of primary resistance and relapses It is therefore important to continue to understand the molecular mechanisms involved in melanoma development and progression to improve current treatments and or to discover new anti-metastatic melanoma treatments

Drugs such as the alkylating agents temozolomide and fotemustine or vemurafenib trigger senescence-like phenotypes in melanoma cells Although senescence is a process that limits the proliferation of cells it is now known that senescent cells secrete factors that exert a pro-tumoral role If many studies have focused on the role of the soluble factors of this secretome the potential existence and the role of insoluble factors remain undetermined Preliminary results from the investigators laboratory indicate the presence in the senescent secretome of exosomes microvesicles involved in intercellular communication immunomodulatory functions and tumorigenesis The exovesicules discharged by a cell in its environment are the subject of increasing interest in oncology as a prognostic factor and marker of therapeutic response Several studies showed that these vesicles shape the tumor microenvironment and contribute to the migration of cancer cells

This project aims to study the effect of exosomes produced by senescent melanoma cells in the development and progression of melanoma in vitro and in vivo using cell cultures and animal models In addition the investigator propose a pilot study whose objective is to determine the effect of vemurafenib on production quantity size and composition of nanovesicles produced by patients with advanced unresectable or metastatic melanoma The investigator hope to show that exosomes participate in the process of drug resistance and relapse with the goal of developing with the exosomes study theranostic tools for personalized care in patients

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None